Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Clin Cancer Res. 2013 Mar 13;19(9):2342–2354. doi: 10.1158/1078-0432.CCR-12-2623

Figure 6.

Figure 6

LY294002 attenuates inflammation and mast cell degranulation in IL-10−/− mice in vivo, and tumor cell proliferation and invasion ex vivo. (A) Quantification of % mean ± standard error CAE+ cells per total nuclei in LY294002 untreated and treated IL-10−/− mice. (B) Quantitation of % mean ± standard error in vivo mast cell degranulation per total mast cells in the colon of the LY294002 untreated or treated IL-10−/− mice (% in situ degranulation = total purple mast cells X 100 / total mast cells in LY294002 untreated or treated IL-10−/−). (C) Quantitation of % in vitro β-hexosaminidase release from GMMCs after treatment of carrier or 5 µM or 10 µM LY294002. (D) Quantitation of mean ± standard error CT44 mouse colon cancer proliferation at 24 hour time point in response to carrier or 10 µM LY294002 treated GMMC conditioned medium. (E) Quantification of mean ± standard error CT44 cell invasion/well in response to carrier or 10 µM LY294002 treated GMMC conditioned medium. (F) CAE staining at 100X & 200X magnification respectively of IL-10−/− mice 56 days post Piroxicam ± LY294002 treatment, small arrow indicate CAE positive cells. (G) Toluidine blue staining at 100X & 1000X magnification respectively of IL-10−/− mice 56 days post Piroxicam ± LY294002 treatment, large black arrow indicates magnified, purple degranulating or blue non-degranulating mast cells. (H) CT44 mouse colon cancer cell invasion in response to conditioned medium obtained either carrier or LY294002 treated GMMCs. Scale bar in (F) and upper panel of (G) = 50 µm, Scale bar for 1000X magnification for G = 20 µm, * P < 0.05 represents the result of Student t test.

HHS Vulnerability Disclosure